MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 30, 2017, Matinas BioPharma Holdings, Inc. (the Company)
announced that, upon the recommendation of the Nominating and
Corporate Governance Committee (the Committee) of the Board of
Directors (the Board) of the Company, the Board appointed Dr.
Eric J. Ende, age 48, effective April 3, 2017, to serve as a
member of the Board. Dr. Ende will hold this position from April
3, 2017 until the next annual meeting of the Companys
shareholders or until his successor is elected and qualified,
subject to his earlier resignation or removal. Dr. Ende will also
serve on the audit committee and compensation committee of the
Board.
Since 2009, Dr. Ende has served as president of Ende BioMedical
Consulting Group, a privately-held consulting company which is
focused on helping life sciences companies raise capital,
identify licensing partners, and optimize corporate structure as
well as analyzing both private and public investment
opportunities for clients within the life sciences industry. Dr.
Ende serves as co-founder, chief executive and chief financial
officer of WellFit Holdings, LLC, a private company focused on
developing fitness technologies. In addition, Dr. Ende consulted
with Icahn Enterprises in their efforts to appoint board members
at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende served
on the board of directors and as a member of the audit and risk
management committee of Genzyme Corp. (NASDAQ: GENZ) from 2010
until it was acquired by Sanofi (NSYE: SNY) in 2011. Dr. Ende is
currently serving on the Technology Transfer Committee of Mount
Sinai Innovation Partners and served as the Chairman of the
Unsecured Creditors Committee overseeing the bankruptcy of
Egenix, Inc. From 2002 through 2008, Dr. Ende was the senior
biotechnology analyst at Merrill Lynch. From 2000 through 2002,
Dr. Ende was the senior biotechnology analyst at Banc of America
Securities and, from 1997 to 2000, he was a biotechnology analyst
at Lehman Brothers. Dr. Ende received an MBA in Finance
Accounting from NYU Stern Business School in 1997, an MD from
Mount Sinai School of Medicine in 1994, and a BS in Biology and
Psychology from Emory University in 1990.
Dr.Ende will participate in the Companys standard non-employee
director compensation plan, including an initial option grant to
purchase 150,000 shares of the Companys common stock upon joining
the Board and an annual retainer fee of $35,000 (payable in
restricted stock).
| Item 7.01. | Regulation FD Disclosure. |
On March 30, 2017, the Company issued a press release announcing
the appointment of Dr. Ende to its Board of Directors.A copy of
the press release is furnished as Exhibit99.1 hereto. In
accordance with General Instruction B.2 of Form8-K, the
information in Item 7.01 of this Current Report on Form8-K,
including Exhibit99.1, shall not be deemed filed for the purposes
of Section18 of the Exchange Act, or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d)Exhibits | ||
| 99.1 | Press Release dated March 30, 2017 |
About MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB)
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections. MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Recent Trading Information
MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) closed its last trading session up +0.01 at 2.96 with 370,025 shares trading hands.